Go To Global Site
Welcome to UCB in the United States



UCB’s Commitment to Students Living with Epilepsy

Each year, UCB has the honor of awarding our UCB Family Epilepsy Scholarship to deserving individuals living with epilepsy, their family members, and caregivers to help them fulfill their dreams. We realize that to truly make an impact on patients’ lives, we must go beyond developing and delivering medicines, and we are committed to helping patients and their families receive the financial support they need to live their best lives possible.



UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older



Together Towards Recovery: How a Year of Distance Has Brought Us Closer to the Needs of Patients

With more than 20 years of experience in caring for people living with epilepsy, our goal has always been to know and understand the day-to-day experiences of people living with the disease better than anyone. Over the past year this has been especially true, and the challenges we’ve faced have reinvigorated our commitment to the overall emotional and physical well-being of patients. Read more from UCB’s Head of U.S. Neurology, Mike Davis, about how UCB is finding new ways to better connect with patients and improve their day-to-day experience.



UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio



New Digital Treatment Tracker for People Living with Epilepsy

During Epilepsy Awareness Month, as part of our commitment to providing solutions that positively impact the lives of patients with neurological conditions, we enthusiastically announce a new initiative with Medisafe – the leading integrated medication management platform, personalized to engage patients and deliver outcomes.  



Michele’s Story: Living with Tonic-Clonic Seizures

Michele has lived with tonic-clonic seizures since the age of 28 when she experienced her first seizure while swimming in a pool. This Epilepsy Awareness Month, read about her journey to seizure freedom. 



UCB Grants Scholarships to People Living with Epilepsy

33 Winners of the UCB Family Epilepsy Scholarship demonstrate UCB’s commitment to patients.



Closing the Epilepsy Treatment Gap: Understanding the Role of Social Determinants of Health

The COVID-19 pandemic is changing the way we view health care. It

has brought to the forefront of public conversation sobering truths about how social and racial disparities impact the health outcomes of underserved populations in the United States. Often, we attribute an individual’s health solely to the quality of health care they receive when in fact, a host of factors that occur outside clinical walls can play an even greater role in a person’s well-being. Social Determinants of Health (SDH) are the conditions in which people are born, grow, live, work and age, such as socioeconomic factors, housing, physical environment, education, employment, social support and access to health care. SDH can affect a wide range of health outcomes and quality of life, especially for individuals battling chronic illnesses like epilepsy.



UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform

Six poster presentations highlight clinical data on NAYZILAM® (midazolam) nasal spray CIV and BRIVIACT® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research

Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.



Press Release: UCB acquires Engage Therapeutics: Staccato Alprazolam - A potential solution for acute on-demand seizure management for people living with epilepsy

• Underlines UCB’s leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure